| Autor: |
Khokhlova SV, Cherkasova MV, Orel NF, Limareva SV, Bazaeva IIa, Gorbunova VA |
| Jazyk: |
ruština |
| Zdroj: |
Vestnik Rossiiskoi akademii meditsinskikh nauk [Vestn Ross Akad Med Nauk] 2013 (11), pp. 115-21. |
| Abstrakt: |
Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabected in with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6-12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients. Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
